lymphatic type that has a lower risk. However, the most frequent complication of atypical vascular lesions is postsurgical recurrence, rather than transformation to angiosarcoma, with the development of new lesions in the same radiation field, the so-called field effect. 5 For this reason, patients with a history of radiotherapy should be carefully monitored for vascular eruptions on the irradiated skin.
Phototherapy is a safe, efficacious and cost-effective treatment for many skin conditions. A typical course of hospital-based phototherapy involves patients attending three times a week for anywhere between 20-30 treatments. This is perceived as inconvenient by some, which may affect their treatment choice and compliance. Home phototherapy may offer an effective and safe alternative, potentially removing the barriers of inconvenience and financial cost by emphasising patients' autonomy. 1 The current model for phototherapy delivery in Auckland, the largest city in New Zealand by population, is predominantly via centralised public-hospital-based outpatient care through two centres based in the central city (the study centre) and a southern suburb. The study centre covers a wide area, extending from the hospital itself into the neighbouring regions up to 180 km away (Fig. 1) . This is in contrast with some phototherapy services overseas that utilise a hub and spoke delivery model involving the use of both satellite units and home phototherapy. 2 We conducted prospective, observational, single-centre study, whose aim was to assess the potential cost and loss of productivity incurred by patients given hospital-based phototherapy. Approval was obtained from the local health authority. Patients requiring phototherapy were invited to participate by answering three questionnaires at scheduled times during their course of treatment (at the beginning, in the middle and towards end of the course). The questionnaire aimed to assess the impact that travelling for each treatment had on the patients and any accompanying person, in terms of time and cost incurred in relation to the distance travelled, as well as to obtain feedback on the treatment. The patients were also asked if they would prefer a different method of phototherapy delivery in the final questionnaire.
Altogether 20 patients completed the study, therefore 60 questionnaires were analysed ( Table 1 ). The mean waiting time for commencing phototherapy from referral was 3 months. Most of the group (14 patients) travelled less than 20 km to come for treatment, with a mean travel distance of 14.9 km (range 3-17 km) and a mean travel time of 52 min (range 9-60 min). Six patients travelled more than 20 km to come for the treatment, with a mean travel time of 112 min (range 25-180 min) and the mean distance travelled of 78.7 km (range 20-170 km). This corresponded with higher mean travel costs excluding petrol Letter to the Editor e79 (NZ$9.39 vs NZ$6.76 per trip), with greater levels of dissatisfaction than those who travelled less (56 vs 21%). Based on this information and using the current New Zealand minimum wage set at NZ$15.75/h, a patient who travelled more than 20 km could have lost at least NZ$315 in hourly wages alone over the course of the 20 treatments due to the extended travel times compared to those travelling less than 20 km. In addition, the same patient could have paid up to NZ$931.40 more than the patient who lived nearer in petrol cost, based on the current official New Zealand Inland Revenue Department mileage reimbursement rate of NZ$0.73/km. Not surprisingly, most of the patients were more likely to support alternative methods of treatment delivery (85%), if it was available.
These results show that our patients, who come from a self-selected pool of motivated patients, incur a substantial cost to attend hospital-based phototherapy. This is a significant burden as many of our patients have a low income. 2 This cost may also be an underestimate, as there are many intangible costs such as a delay in starting treatment, time taken off study and finding an accompanying person, which are difficult to quantify.
This study supports the recent published literature that alternative delivery models, including home phototherapy, need to be considered. Home-based phototherapy was found to be just as effective and safe as phototherapy in the hospital setting, with similar improvements in quality of life but with greater patient satisfaction derived from reduced travel time. 3 Other studies have shown that patients who underwent home phototherapy reported better compliance and satisfaction. 3 The availability of home phototherapy varies widely from country to country. In the UK, with a similar public health system as New Zealand, to our knowledge there is currently only one home phototherapy service, which was set up to provide equality of access to phototherapy.
Research Letter Dear Editor,
Remote partner assisted skin self-examination skills training of melanoma survivors and their partners A structured partner assisted skin self-examination (SSE) training program delivered in the office to melanoma survivors and their partners (pairs) demonstrated greater knowledge, skills, and accuracy among trained pairs than controls.
1,2
While previous research supported this promising training program, the real-world constraints on delivering office-based education may diminish sustainability due to interruption in clinical workflow and cost of healthcare professionals providing training. This randomized clinical trial evaluated the effect of remote training on knowledge, attitudes, and performance of SSE in comparison with controls. The secondary outcome was identification of concerning moles by pairs and whether these moles were biopsied (indicating consistency between physicians' and pairs' assessment of the mole).
Pairs were randomized to control or mailed the MoleScore TM Workbook, Scorecard for Moles (a diary), 3 and
Body Map booklet. The melanoma survivor and the partner separately answered previously reported online surveys 1 prior to randomization and 9 months later. Skin biopsy of a concerning mole was confirmed by review of the electronic medical record. Participants provided written informed consent and each received $25 to complete each online assessment.
RESULTS
Forty-six percent of 362 melanoma survivors enrolled (Fig. S1 ). There were no significant demographic differences between the controls and those receiving remote 
